bu-abdullaziz
عضو مميز
- التسجيل
- 11 ديسمبر 2003
- المشاركات
- 1,777
Buy at $4, Sell at $6 + (Great Growth Potential)
StemCells, Inc. is a biotechnology company that has been gaining an increasing amount of attention from medical industry professionals, scientists, individual investors & venture capitalists across the globe. StemCells, Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. Further information about the Company is available on its web site at www.stemcellsinc.com. Stem Cell research has been gaining an unprecedented amount of attention worldwide, and for good reason. Stem Cells may hold the cure and/or treatment for serious injuries & illnesses. The potential that stem cells hold is truly phenomenal, and as of today, millions of people around the world are counting on further research on stem cells to quite possibly reverse their "so-called" permanent injuries & prevent serious illnesses from occurring in the future. Stem Cell research has been an extremely hot & important topic of debate for the two U.S. presidential candidates during their campaigns, and billions of people worldwide have strong feelings about it. The stock is currently in play, and based on our chart & market analysis of this biotech stock, a price surge is highly probable regardless of who wins the presidency. Christopher Reeves, who unfortunately passed away recently, the debate whether stem cell research should increase has heated up. In recent news, Stem Cells, Inc. was able to raise $22.5 Million in new equity financing. The stock has close to 20 Million in trading volume, and we project that the stock will be reaching new highs after the election. Over the past 2 weeks, the stock has doubled in price, and anticipate the stock will continue its uptrend up to $6 +. Now is a prime to pick up a few shares before the stock increases in value any more. The penny stock has an ask price of $4.13, and a bid price of $4.12, with a very small spread. Be sure to buy in the dip!
Check out recent company news, quotes & a chart here: http://finance.yahoo.com/q?s=stem
StemCells, Inc. (Nasdaq:STEM - News) announced today that it has entered into definitive agreements with institutional investors with respect to the registered direct placement of 7,500,000 shares of its common stock at a purchase price of $3.00 per share, for gross proceeds of approximately $22,500,000. C.E. Unterberg, Towbin, LLC and Shoreline Pacific, LLC served as placement agents for the transaction.
The transaction is expected to be consummated within the next few days following satisfaction of certain customary closing conditions contained in the definitive transaction agreements.
StemCells sold these shares under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission.
Check out their recent press releases:
• StemCells Completes Equity Financing
Mon 4:00am - Business Wire
• Elections to Move Stocks in Short Term
Sun 2:56pm - Reuters
• STEMCELLS INC Files SEC form 10-Q, Quarterly Report
Fri, Oct 29 - EDGAR Online
• [external] Biotech, pharma sectors higher; StemCells slides
Tue, Oct 26 - at CBS MarketWatch
• [external] Health Stocks in Motion
Tue, Oct 26 - TheStreet.com
• [external] HEADLINE STOCKS - U.S. stocks to watch on Oct. 26
Tue, Oct 26 - at Reuters
• [external] StemCells shares fall 24 percent
Tue, Oct 26 - at Reuters
• StemCells Shares Fall on Wider 3Q Loss
Tue, Oct 26 - Associated Press
• STEMCELLS INC Files SEC form 8-K, Results of Operations, Other Events, Financial Statements and Exhibits
Tue, Oct 26 - EDGAR Online
• StemCells Raises $22.5 Million in New Equity Financing
Tue, Oct 26 - Business Wire
StemCells, Inc. is a biotechnology company that has been gaining an increasing amount of attention from medical industry professionals, scientists, individual investors & venture capitalists across the globe. StemCells, Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. Further information about the Company is available on its web site at www.stemcellsinc.com. Stem Cell research has been gaining an unprecedented amount of attention worldwide, and for good reason. Stem Cells may hold the cure and/or treatment for serious injuries & illnesses. The potential that stem cells hold is truly phenomenal, and as of today, millions of people around the world are counting on further research on stem cells to quite possibly reverse their "so-called" permanent injuries & prevent serious illnesses from occurring in the future. Stem Cell research has been an extremely hot & important topic of debate for the two U.S. presidential candidates during their campaigns, and billions of people worldwide have strong feelings about it. The stock is currently in play, and based on our chart & market analysis of this biotech stock, a price surge is highly probable regardless of who wins the presidency. Christopher Reeves, who unfortunately passed away recently, the debate whether stem cell research should increase has heated up. In recent news, Stem Cells, Inc. was able to raise $22.5 Million in new equity financing. The stock has close to 20 Million in trading volume, and we project that the stock will be reaching new highs after the election. Over the past 2 weeks, the stock has doubled in price, and anticipate the stock will continue its uptrend up to $6 +. Now is a prime to pick up a few shares before the stock increases in value any more. The penny stock has an ask price of $4.13, and a bid price of $4.12, with a very small spread. Be sure to buy in the dip!
Check out recent company news, quotes & a chart here: http://finance.yahoo.com/q?s=stem
StemCells, Inc. (Nasdaq:STEM - News) announced today that it has entered into definitive agreements with institutional investors with respect to the registered direct placement of 7,500,000 shares of its common stock at a purchase price of $3.00 per share, for gross proceeds of approximately $22,500,000. C.E. Unterberg, Towbin, LLC and Shoreline Pacific, LLC served as placement agents for the transaction.
The transaction is expected to be consummated within the next few days following satisfaction of certain customary closing conditions contained in the definitive transaction agreements.
StemCells sold these shares under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission.
Check out their recent press releases:
• StemCells Completes Equity Financing
Mon 4:00am - Business Wire
• Elections to Move Stocks in Short Term
Sun 2:56pm - Reuters
• STEMCELLS INC Files SEC form 10-Q, Quarterly Report
Fri, Oct 29 - EDGAR Online
• [external] Biotech, pharma sectors higher; StemCells slides
Tue, Oct 26 - at CBS MarketWatch
• [external] Health Stocks in Motion
Tue, Oct 26 - TheStreet.com
• [external] HEADLINE STOCKS - U.S. stocks to watch on Oct. 26
Tue, Oct 26 - at Reuters
• [external] StemCells shares fall 24 percent
Tue, Oct 26 - at Reuters
• StemCells Shares Fall on Wider 3Q Loss
Tue, Oct 26 - Associated Press
• STEMCELLS INC Files SEC form 8-K, Results of Operations, Other Events, Financial Statements and Exhibits
Tue, Oct 26 - EDGAR Online
• StemCells Raises $22.5 Million in New Equity Financing
Tue, Oct 26 - Business Wire